<DOC>
	<DOCNO>NCT00696930</DOCNO>
	<brief_summary>Subjects screen determine OctreoScan® uptake . And upon meet eligibility criterion , 90 subject complete symptom assessment scale baseline throughout study specific time point . Actual treatment consist three six-week cycle fix total dose 13.3 GBq ( 360 mCi ) 90Y-SMT487 . The total dose divide three equal dos administer single activity 4.4 GBq ( 120 mCi ) 90Y-SMT487 every six week three cycle . An amino acid infusion administer along dose . Long-term follow occur 6 12 month Day 1/ Cycle 1 . Survival assess every six month .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety 90Y-SMT487 Subjects With Symptomatic Malignant Carcinoid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Edotreotide</mesh_term>
	<criteria>1 . Life expectancy &gt; 6 month . 2 . Subjects must distant metastasis . 3 . Subjects must able discontinue Sandostatin LAR treatment least 1 month prior Day 1/Cycle 1 ; last dose Sandostatin LAR must 60 day prior first OctreoTher™ dose . For subcutaneous Sandostatin discontinuation 12 hour . Subjects take long act somatostatin analogue must discontinue analogue least 2 time dose interval . 4 . Upon baseline disease assessment , subject must least 1 measurable site disease either never irradiate measurable lesion previously irradiate ; lesion since demonstrate progression base SWOG response criterion . 5 . Subjects must state agree statement `` I symptoms cancer bother . '' Subjects must fail gain complete symptom control despite optimal attempt somatostatin therapy judgement physician . 1 . Chemotherapy , biologic therapy investigational therapy within 4 week Day 1 . 2 . Surgery , hormonal therapy ( include somatostatin analogue ) radiation , within 2 week Day 1 . 3 . Subjects know brain metastasis unless metastasis treat stabilize least six month prior study start . 4 . Subjects receive high dose OctreoScan therapy radiolabelled somatostatin therapy systemic radiolabelled therapy ( e.g . MIBG ) treatment metastatic carcinoid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Malignant Carcinoid Tumors</keyword>
</DOC>